Active, not recruiting
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
NCT03502733
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- UT MD Anderson Cancer Center Houston, Texas, United States